PRECISION BIOSCIENCES INCDTIL财报
Precision BioSciences, Inc. is a publicly traded American clinical stage gene editing company headquartered in Durham, North Carolina. Founded in 2006, Precision is focused on developing both in vivo and ex vivo gene editing therapies using its proprietary "ARCUS" genome editing platform.
DTIL Q4 2025 Key Financial Metrics
营收
$34.2M
毛利润
N/A
营业利润
$12.5M
净利润
$20.1M
毛利率
N/A
营业利润率
36.6%
净利率
58.9%
同比增长
5261.1%
EPS
$2.62
资金流向
PRECISION BIOSCIENCES INC Q4 2025 财务摘要
PRECISION BIOSCIENCES INC reported revenue of $34.2M (up 5261.1% YoY) for Q4 2025, with a net profit of $20.1M (up 213.5% YoY) (58.9% margin). Cost of goods sold was N/A.
核心财务指标
| 总营收 | $34.2M |
|---|---|
| 净利润 | $20.1M |
| 毛利率 | N/A |
| 营业利润率 | 36.6% |
| 报告期 | Q4 2025 |
PRECISION BIOSCIENCES INC 年度营收
PRECISION BIOSCIENCES INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $34.3M). Click any linked year to see what changed vs the prior 10-K.
PRECISION BIOSCIENCES INC 季度营收与净利润历史
PRECISION BIOSCIENCES INC quarterly results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| 季度 | 营收 | 营收同比 | 净利润 | 净利率 |
|---|---|---|---|---|
| Q4 2025 | $34.2M | +5261.1% | $20.1M | 58.9% |
| Q3 2025 | $13.0K | -97.7% | $-21.8M | -167476.9% |
| Q2 2025 | $18.0K | -100.0% | $-23.5M | -130666.7% |
| Q1 2025 | $29.0K | -99.8% | $-20.6M | -70913.8% |
| Q4 2024 | $638.0K | -90.9% | $-17.7M | -2781.3% |
| Q3 2024 | $576.0K | -95.6% | $-16.4M | -2851.6% |
| Q2 2024 | $49.9M | +152.2% | $32.7M | 65.6% |
| Q1 2024 | $17.6M | +100.3% | $8.6M | 48.8% |
利润表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 营收 | $17.6M | $49.9M | $576000 | $638000 | $29000 | $18000 | $13000 | $34.2M |
| 同比增长 | 100.3% | 152.2% | -95.6% | -90.9% | -99.8% | -100.0% | -97.7% | 5261.1% |
资产负债表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 总资产 | $184.7M | $165.8M | $153.3M | $136.4M | $124.4M | $108.9M | $93.5M | $154.4M |
| 总负债 | $147.5M | $91.1M | $88.4M | $80.0M | $75.1M | $74.9M | $76.9M | $62.2M |
| 股东权益 | $37.2M | $74.7M | $64.9M | $56.4M | $49.3M | $34.1M | $16.6M | $92.2M |
现金流量表
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| 经营性现金流 | $-19.0M | $-14.9M | $-5.9M | $-18.7M | $-19.1M | $-20.3M | $-15.3M | $-11.3M |